



FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

Rita Sofia Bettencourt Silva

TSH, FT3 and FT4 were not associated with changes in body composition
in HIV-infected patients on combined antiretroviral therapy

Mestrado Integrado em Medicina

Área: Endocrinologia

Trabalho efetuado sob a Orientação de:

Dra. Paula Freitas

Trabalho organizado de acordo com as normas da revista

BMC Infectious Diseases

março, 2012

FMUP

Eu, Rita Sofia Bettencourt Silva, abaixo assinado, nº mecanográfico 050801227, estudante do 6º ano do Mestrado Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 21/03/2012

Assinatura: Rita Sofia Bettencourt Silva

Nome: Rita Sofia Bettencourt Silva

Endereço eletrónico: ritabettsilva@gmail.com

Telemóvel: +351 91 939 40 81

Número do Bilhete de Identidade: 13241843

Título da Dissertação/~~Monografia~~ (cortar o que não interessa):

TSH, FT3 and FT4 were not associated with changes in body composition in HIV-infected patients on combined antiretroviral therapy

Orientadora:

Dra. Paula Freitas

Ano de conclusão: 2012

Designação da área do projeto:

Endocrinologia

É autorizada a reprodução integral desta Dissertação/~~Monografia~~ (cortar o que não interessar) para efeitos de investigação e de divulgação pedagógica, em programas e projetos coordenados pela FMUP.

Faculdade de Medicina da Universidade do Porto, 21/03/2012

Assinatura: Rita Sofia Bettencourt Silva

DEDICATÓRIA

Aos meus pais, pelo amor incondicional, suporte emocional e liberdade para fazer as minhas escolhas;

À Beatriz, minha irmã, confidente e companheira de casa, com quem partilho diariamente todos os bons e maus momentos;

À Maria João Camões e Raquel Marçôa, pela amizade que nos une e pelo apoio prestado durante o desenvolvimento deste trabalho;

Ao meu tio Luís, pelos conhecimentos que me transmitiu e pelo seu incentivo para me superar todos os dias.

RESUMO

INTRODUÇÃO: Os doentes infetados pelo vírus da imunodeficiência adquirida (VIH) em terapêutica antirretrovírica combinada (TARC) podem ter distúrbios metabólicos, lipodistrofia e disfunção tiroideia. Tem sido investigado o impacto potencial de alterações minor da função tiroideia na composição corporal em doente eutiroideus não infetados pelo VIH, mas não na população infetada pelo VIH. Os objetivos deste estudo foram comparar os níveis de TSH, T3L e T4L nos doentes eutiroideus com e sem lipodistrofia [definida pela clínica e pela razão massa gorda (RMG)] e em quatro grupos de composição corporal; e avaliar a possível relação entre a TSH, T3L e T4L e parâmetros demográficos, antropométricos, infecciosos e metabólicos.

MÉTODOS: Estudo transversal incluindo 352 adultos caucasianos não institucionalizados infetados pelo VIH-1 sob TARC. Foram avaliados dados demográficos, caracterização da infeção VIH, função tiroideia, características antropométricas, composição corporal por DXA e parâmetros metabólicos.

RESULTADOS: Não houve diferenças significativas entre a mediana de TSH, T3L e T4L de acordo com a presença de lipodistrofia (definida pela clínica e pela RMG) e os quatro grupos de composição corporal. A TSH estava positivamente correlacionada com a idade e negativamente com a contagem de células CD4. Na análise multivariada, depois de ajustar para a idade, género e índice de massa corporal (IMC), a TSH permaneceu positivamente associada com a idade e negativamente com a contagem de células CD4. A T3L estava positivamente correlacionada com a duração da infeção por VIH e negativamente com a idade, pressão arterial sistólica (PAS) e pressão arterial diastólica (PAD). Na análise multivariada, não houve associações significativas com a T3L. A T4L estava positivamente correlacionada com a duração da infeção e negativamente com a PAD, colesterol total e C-LDL. Na análise univariada, a FT4 estava negativamente associada com o IMC, colesterol total e C-LDL, mas no modelo de regressão linear múltiplo apenas a associação com o LDL-C permaneceu significativa.

CONCLUSÕES: Não houve diferenças nos valores de TSH, T3L e T4L de acordo com a composição corporal em doentes eutiroideus infetados pelo VIH. Os níveis de TSH estavam associados positivamente com a idade e negativamente com a contagem de células CD4, mesmo na análise multivariada. Os doentes eutiroideus podem ter anomalias lipídicas e pressão sanguínea elevada.

PALAVRAS-CHAVE: VIH, terapêutica antirretrovírica, tiroide, lipodistrofia, composição corporal, razão massa gorda, pressão sanguínea, dislipidemia.

TITLE

TSH, FT3 and FT4 were not associated with changes in body composition in HIV-infected patients on combined antiretroviral therapy

Author

Rita Bettencourt Silva

Affiliation

Sixth year student of the Integrated Master Degree in Medicine, Faculty of Medicine of Porto University, Porto, Portugal

Correspondence

Rita Bettencourt Silva

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João

Alameda Professor Hernâni Monteiro

4200-319 Porto

Portugal

Phone: +351 91 939 40 81

E-mail: ritabettsilva@gmail.com

ABSTRACT

BACKGROUND: Human immunodeficiency virus (HIV)-infected patients on combined antiretroviral therapy (cART) may have metabolic disorders, lipodystrophy and thyroid dysfunction. It has been investigated the potential impact of minor changes in thyroid function on body composition of euthyroid HIV non-infected patients, but not in HIV-infected population. The aims of this study were to compare TSH, FT3 and FT4 levels in euthyroid patients with and without lipodystrophy [defined by clinical and by fat mass ratio (FMR)] and in four groups of body composition; and to assess the possible relationship between TSH, FT3 and FT4 and demographics, anthropometrics, infectious and metabolic parameters.

METHODS: Cross-sectional study including 352 HIV-1-infected non-institutionalized Caucasian adults on cART. Demographic data, HIV infection characterization, thyroid function, anthropometric features, body composition by DXA and metabolic parameters were evaluated.

RESULTS: There were no significant differences between the median of TSH, FT3 and FT4 according to the presence of lipodystrophy (defined by clinical and by FMR) and the four groups of body fat composition. TSH was positively correlated with age and negatively with CD4 cell count. In multivariate analysis, after adjustment for age, gender and body mass index (BMI), TSH remained positively associated with age and negatively associated with CD4 cell count. FT3 was positively correlated with duration of HIV infection and negatively with age, systolic blood pressure (SBP) and diastolic blood pressure (DBP). In multivariate analysis, there were no significant associations with FT3. FT4 was positively correlated with duration of infection and negatively with DBP, total cholesterol and LDL-C. In univariate analysis, FT4 was negatively associated with BMI, total cholesterol and LDL-C, however in the multiple linear regression model (with age, gender and BMI as covariates) only the association with LDL-C remained significant.

CONCLUSIONS: There were no differences in TSH, FT4 and FT3 values according to body composition in euthyroid HIV-infected patients. TSH levels were positively associated with age and negatively with CD4 cell count, even in multivariate analysis. Euthyroid patients can have lipid abnormalities and raised blood pressure.

KEYWORDS: HIV, antiretroviral therapy, thyroid, lipodystrophy, body composition, fat mass ratio, blood pressure, dyslipidemia.

BACKGROUND

The acquired immune deficiency syndrome (AIDS), primarily reported in 1981, became a leading cause of mortality worldwide [1]. With the successful introduction of combined antiretroviral therapy (cART) in 1996, human immunodeficiency virus (HIV)-related morbidity and mortality have declined substantially [1, 2]. However, and due to an increased survival, there are more and more people living with this infection. At the end of 2010 it was estimated that nearly 34 million adults and children were living with HIV infection worldwide [2].

The use of cART has been associated with many side effects, including lipodystrophy, dyslipidemia, insulin resistance, increased blood pressure, decreased bone mineral density and dysfunction of the adrenal, gonadal and thyroidal axes [3-5]. Önen suggested that these comorbidities are not part of the “normal” aging process [4]. However, the mechanisms responsible for cART-related metabolic disorders are not fully understood and there is a growing recognition that inflammatory cytokines and HIV infection by itself can be the etiologic agents of these metabolic abnormalities [5, 6].

Lipodystrophy is characterized by selective loss of adipose tissue from particular anatomical regions and can be localized or generalized [7]. Acquired lipodystrophies occur more frequently than the inherited types and the most prevalent subtype in the clinic is acquired partial lipodystrophy related to cART in HIV-infected patients [7, 8]. With the beginning of molecular genetic era, congenital and familial types were associated with mutant gene products and not only characterized by clinical features. However, the mechanisms responsible for the relationship between HIV and lipodystrophy remain partially unknown [7]. HIV-associated lipodystrophy syndrome is characterized by loss of subcutaneous fat (lipoatrophy) from the face and limbs with or without deposition of excess fat (lipohypertrophy) in the neck and upper back (causing a double chin and a buffalo hump), abdomen and trunk, resulting in peripheral fat wasting and central adiposity [7-9]. Some patients have peripheral lipoatrophy, others have isolated abdominal prominence and a substantial portion has mixed forms including both phenotypes [9]. HIV-associated lipodystrophy has been linked to components of metabolic syndrome (MS), such as high blood pressure, dyslipidemia and insulin resistance, leading to an increased cardiovascular disease risk [3, 7]. The relationship between cART and fat redistribution is associated with prolonged duration of treatment and is highly linked to the use of protease inhibitors (PI) drugs,

although it has been also related to other antiretroviral drugs [3, 8, 9]. In his clinical review, Chen reported that prevalence of lipodystrophy among HIV-infected patients was highly variable according to different authors, ranging between 8% and 84% (due to different definition and diagnosis criteria). He noticed that near 40% of patients treated with PI developed lipodystrophy [8].

Thyroid hormones regulate the metabolism and function of many tissues, such as liver, heart, skin, muscle and adipose tissue. They are involved via thyroid hormone receptors (TRs) in adipogenesis and adipose tissue lipogenesis and lipolysis [10, 11]. All the isoforms of TRs (both TRA1 and TRB1) are expressed in white adipose tissue [12]. Moreover, the monocarboxylate transporter 8 (MCT8) is a thyroid-hormone-specific transporter that is ubiquitously expressed, including in human subcutaneous adipose tissue (SAT) [12]. Overt hypothyroidism is clearly associated with body weight excess and obesity, but the potential impact of minor changes in thyroid function on anthropometric measures of euthyroid HIV non-infected patients remains under investigation [13-16]. So far there are still no studies exploring this relationship among HIV-infected patients.

Due to the important role of TH on adipocyte metabolism and as HIV-associated lipodystrophy results from changes in adipose tissue, we hypothesized that minor changes in thyrotropin (TSH), free 3,5,3'-triiodothyronine (FT3) and free thyroxine (FT4) may have a significant role in the peculiar body fat redistribution of these patients.

The aims of the current study were (1) to compare the levels of TSH, FT3 and FT4 in euthyroid patients with and without lipodystrophy [(defined by clinical and by fat mass ratio (FMR)] and in four different groups of body composition (no lipodystrophy; isolated central fat accumulation; isolated lipoatrophy; and mixed forms of lipodystrophy); (2) and to assess the possible relationship between TSH, FT3 and FT4 and demographic, anthropometric, infectious and metabolic parameters.

METHODS

Subjects and study design

As part of a cross-sectional study, 352 clinically stable HIV-infected non-institutionalized Caucasian adults (234 men and 118 women) receiving antiretroviral therapy, consecutively referred from the Infectious Diseases Outpatient Clinic were evaluated. Only patients on cART were included, because lipodystrophy is related with this therapy [8]. Patients without thyroid function test results and with thyroid dysfunction (such as overt and subclinical hypothyroidism, overt and subclinical hyperthyroidism, Graves' disease, Hashimoto thyroiditis, papillary thyroid carcinoma, toxic multinodular goiter, isolated low FT4 level and nonthyroidal illness syndrome) were excluded. The study protocol was approved by the Hospital Ethics Committee and each patient provided informed consent.

Clinical assessments

For each patient the following information was collected using a standardized protocol: demographic data (age, gender, smoking status), history of hypertension, diabetes and use of antihypertensive, antidiabetic and lipid-lowering drugs, duration of HIV infection, HIV infection risk factors, duration of cART and characterization of the infection. The "Centers for Disease Control and Prevention" (CDC) criteria for staging of HIV infection were used [17]. The HIV infection risk factors were classified into four different groups: intravenous drug use; homosexual and bisexual contact; heterosexual contact; and other (hemophiliacs, transfused patients and unknown risk). Antiretroviral treatment analysis included only the last therapy used up to collecting data, the type of drugs used and the total duration of cART since infection diagnoses.

Weight, height, resting blood pressure, circumferences of neck, waist, hip, thigh and arm were measured, as previously described [18, 19]. The subjects were standing upright, with the face directed forwards, arms by the sides and gluteal muscles and shoulders relaxed. All measurements were taken by the same well-experienced physician with standard techniques [20]. Body weight was measured using a TANITA scale (Tanita®, model TBF 300), with patients wearing light clothes without shoes. Height was measured to the nearest centimetre in the standing position using a wall stadiometer (Holtain Limited

Crymych, Dyfed[®]). Body mass index (BMI) was calculated as weight in kilograms divided by the squared height in metres. Resting blood pressure was measured on a single occasion using a standard mercury sphygmomanometer with the cuff on the left upper arm.

Clinical lipodystrophy (CL) was defined as a peripheral lipoatrophy with or without a central fat accumulation assessed by both patient and practitioner [21]. Patients were classified as without CL when none of the previously described features were present. Presence of central fat accumulation or abdominal prominence was defined by the measurement of waist circumference using the International Diabetes Federation (IDF) criteria for MS, which recommends that the threshold for abdominal obesity must be ≥ 94 centimetres in men and ≥ 80 centimetres in women [22]. The clinical assessment was performed by the same practitioner. As previously described [21], the patients were placed into four different categories according to the presence or absence of either lipoatrophy or abdominal prominence: 1) No lipodystrophy – patients without clinical lipoatrophy and without abdominal prominence; 2) Isolated central fat accumulation – patients without clinical lipoatrophy and with abdominal prominence; 3) Isolated lipoatrophy – patients with clinical lipoatrophy and without abdominal prominence; 4) Mixed forms of lipodystrophy – patients with clinical lipoatrophy and with abdominal prominence.

Body composition was assessed with whole-body dual-energy X-ray absorptiometry (DXA – Lunar Expert XL). DXA measurement was performed while the patient was in a supine position, with standard positioning of the arms and feet. Markers used in this study for trunk and lower limbs that defined regions of interest were those indicated by the manufacturer. Regional fat mass values were grouped and analyzed for the following anatomical regions: arms, legs, trunk and total body. The FMR was calculated as the ratio between the percentage of the trunk fat mass and the percentage of the lower limbs fat mass ($\text{FMR} = \% \text{ of the trunk fat mass} / \% \text{ of the lower limb fat mass}$) [23, 24].

Laboratory analysis

A venous blood sample was drawn after a 12-hour overnight fast. All the samples were analyzed at the central laboratory of our hospital. Plasma glucose, total cholesterol, low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were determined using automatic standard routine enzymatic methods [18]. CD4 cell count was determined by flow cytometry and plasma HIV-1 RNA loads were measured by a quantitative reverse transcriptase

polymerase chain reaction, with a lower limit of detection of 50 copies/mL. Leptin (human leptin RIA, kit, Linco Research) and adiponectin (human adiponectin RIA, kit, Linco Research) were performed in Nobre Laboratory of the Porto Medical School. The intra-assay and inter-assay precision was 4.6% and 5.0%, respectively, for leptin; the intra-assay and inter-assay precision was 1.78% and 9.25%, respectively, for adiponectin. The MS was defined using the most recent criteria for its clinical diagnosis, proposed by several major organizations (including IDF) in 2009 [22].

TSH, FT3 and FT4 serum levels were measured by a chemiluminescence method (Abbott kit). The normal serum levels for TSH, FT4 and FT3 were defined according with the reference values of the central laboratory of our hospital. The normal range levels were 0.350 to 5.500 mUI/mL for TSH, 0.89 to 1.80 ng/dL for FT4 and 2.3 to 4.2 pg/mL for FT3. Euthyroidism was defined as normal TSH, T3L and FT4 values. The diagnosis of thyroid disease was made from laboratory parameters, clinic database and thyroid medication use.

Statistical analysis

Data were described as mean and standard deviation (SD) for quantitative variables or as median and respective interquartile range (IQR) and compared using the Student-t test or the Mann-Whitney test, respectively. For the comparison between the four groups of fat distribution and the thyroid function parameters the Kruskal-Wallis test was used. Categorical variables were described as counts and proportions, and compared using the chi-square or Fisher's exact test.

For estimating the association between thyroid function parameters (TSH, FT3, FT4) levels and anthropometric, metabolic and body composition characteristics, Spearman correlation coefficients were calculated.

As the dependent variables (TSH, FT3, FT4) had distributions different than the normal, they were log transformed. Using the log transformed dependent variables; multivariate linear regression models were computed to estimate the independent association between thyroid function parameters and metabolic and clinical characteristics.

Statistical analysis was performed using the SPSS version 19.0 software (SPSS Inc., Chicago, Illinois, USA). All probabilities were two tailed and p values <0.05 were regarded as significant.

RESULTS

This study included 352 (234 men and 118 women) euthyroid HIV-infected patients on cART. Table 1 shows the demographic, anthropometric, infectious and cardiovascular risk factors of the sample according to the four groups of body fat distribution. Men had more frequently isolated lipoatrophy or absence of lipodystrophy while women had isolated central fat accumulation and mixed forms of lipodystrophy. Mixed forms were more prevalent in older patients. Regarding smoking status, current smokers were more frequently classified as with no lipodystrophy and with isolated lipoatrophy, while isolated central adiposity and mixed forms were more frequent in those patients that never smoked.

Regarding anthropometric parameters, as expected patients with abdominal prominence (both isolated and mixed forms) had a higher mean of BMI, neck, waist, hip, thigh and arm circumferences and waist/hip ratio. On the other hand, FMR mean was higher in patients with isolated lipoatrophy or mixed forms. The prevalence of isolated lipoatrophy and mixed forms of lipodystrophy were higher in patients with longer duration of HIV infection and cART. As far as HIV risk factors are concerned, patients with isolated lipoatrophy were more frequently intravenous drug users while those into other body composition group had usually heterosexual risk. The prevalence of PI therapy was higher in patients without lipodystrophy or with isolated central fat accumulation. No statistically significant differences were found between the four groups of body composition and viral suppression, CD4 cell count, CDC stage and use of nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI).

Considering metabolic parameters and cardiovascular risk factors, SBP was lower in patients with isolated lipoatrophy, serum glucose was higher when mixed forms were present, total cholesterol and LDL-C levels were significantly higher in patients with isolated central fat accumulation and mixed forms. No differences were observed regarding to DBP, HDL-C and TG. Leptin mean levels were higher in patients with central fat accumulation and mixed forms, while the adiponectin levels were significantly higher in patients without lipodystrophy.

Regarding thyroid function, there were no statistically significant differences between the median of TSH, FT3 and FT4 according to the presence of lipodystrophy defined clinically or by the FMR (Table 2) and the four groups of body fat composition (Table 3). Also, the median of TSH, FT3

and FT4 did not differ significantly according to MS features (Table 4), BMI categories and presence or absence of hypertension (data not shown).

TSH levels were positively correlated with age ($r = 0.134$; $p = 0.013$) and negatively correlated with CD4 cell count ($r = -0.138$; $p = 0.010$) (data not shown). In multivariate analysis, after adjustment for age, gender and BMI, TSH levels remained positively associated with age ($\beta = 0.007$; $p = 0.005$) and negatively associated with CD4 cell count ($\beta = -0.107$; $p = 0.006$) (Table 5).

FT3 levels were positively correlated with duration of HIV infection ($r = 0.109$; $p = 0.048$) and negatively with age ($r = -0.121$; $p = 0.027$), SBP ($r = -0.162$; $p = 0.003$) and DBP ($r = -0.119$; $p = 0.031$) (data not shown). On the other hand, although FT3 levels were negatively associated with gender in univariate analysis ($\beta = -0.002$; $p = 0.001$), after adjustment no significant associations remained (Table 6).

FT4 levels were positively correlated with duration of HIV infection ($r = 0.109$; $p = 0.046$) and negatively with DBP ($r = -0.121$; $p = 0.026$), total cholesterol ($r = -0.142$; $p = 0.009$) and LDL-C ($r = -0.177$; $p = 0.001$) (data not shown). In univariate analysis, FT4 levels were negatively associated BMI ($\beta = -0.008$; $p = 0.035$), total cholesterol ($\beta = -0.001$; $p = 0.018$) and LDL-C levels ($\beta = -0.001$; $p = 0.002$) and tended to be positively associated with duration of HIV infection ($\beta = 0.052$; $p = 0.059$). However in the multiple linear regression model (with age, gender and BMI as covariates) only the association between FT4 and LDL-C remained statistically significant ($\beta = -0.001$; $p = 0.006$) (Table 7).

Interestingly, there was no correlation between TSH, FT3 and FT4 levels (data not shown). Also, there were no statistically significant correlations between TSH, FT3 and FT4 and BMI, cART duration, waist, hip and thigh circumferences, waist/hip ratio, glucose, HDL-C, TG, leptin, adiponectin and fat mass (free, total, upper limbs, lower limbs and trunk) (data not shown).

DISCUSSION

Among HIV-infected patients, some studies have reported that overt thyroid dysfunction occurs between 1% and 2% and subclinical abnormalities may be presented in nearly 35% (often subclinical hypothyroidism) [6, 25, 26].

Studies on the relationship of thyroid function and lipodystrophy are scarce [6, 27, 28]. Some authors described that lipodystrophy wasn't associated with thyroid function abnormalities [6, 27]. Indeed, to knowledge of the authors, this was the first study carried out in HIV-infected patients that investigated the possible relationship between changes of thyroid function at the normal range and lipodystrophy. In our study, there weren't statistically significant differences in TSH, FT3 and FT4 levels between patients with and without lipodystrophy (defined by clinical and by FMR) and in four different groups of body composition. Furthermore, no statistically significant correlation was found between thyroid measurements and anthropometric (BMI, waist, hip and thigh circumferences and waist/hip ratio) or body composition parameters (free, total, upper limbs, lower limbs and trunk fat mass).

Studying lipodystrophy remains difficult because there is a lack of well-defined diagnostic criteria, differences among sample populations and a poor knowledge of all the underlying pathogenic mechanisms [8]. Despite our results, particular observations reported on literature support the hypothesis that changes of thyroid function may be associated with HIV-related lipodystrophy and that this relationship may not be observed by serum thyroid hormone measurements but only in target cell or at the molecular level (probably with differences between lipoatrophic and lipohypertrophic areas). First, HIV infection itself has been associated with higher resting energy expenditure (REE) and cART with decreased REE [29, 30]. Sutinen showed that lipodystrophy by itself was associated with increased REE, since REE was significantly higher in HIV-patients on cART with lipodystrophy compared with those without lipodystrophy, even when adjusted for body weight and fat free mass [31]. Lipodystrophic patients had a higher caloric intake, which can be regulated by thyroid hormones [31]. It was described a negative correlation between REE and TSH levels and an association of minor changes in thyroid function with significant changes in REE [32]. So hypermetabolic state in lipodystrophy may be due to thyroid overactivity or in the upper-normal limit. Finally, a recent study involved patients with familial

partial lipodystrophy (Dunnigan variety) reported that thigh SAT from lipodystrophic patients had lower MCT8 and higher type 2 iodothyronine deiodinase (DIO2) mRNA expression than thigh and abdominal SAT from controls. Then, it was suggested that changes in local thyroid hormones availability occur in lipoatrophic areas [28].

Interestingly in our sample there was no statistically significant correlation between TSH and thyroid hormone levels (both FT3 and FT4). The individual changes on feedback mechanism of pituitary-thyroid axis and the pulsatile TSH secretion pattern can explain this finding [33]. Furthermore, it was suggested that genetic changes can affect the thyrotrophs sensitivity to the feedback regulation by thyroid hormones [34]. Therefore, FT4 and especially FT3 (the active cellular form of thyroid hormone) values may better reflect the physiological actions of thyroid function in different tissues.

TSH levels were positively correlated with age, while FT3 levels were negatively correlated with age. In multivariate analysis, there was a statistically significant positive association between TSH and age, regardless the gender and BMI. In previous studies involving both HIV-infected and uninfected populations, the results are controversial. Different authors had reported an inverse association between age and TSH [35], a positive association in both genders [14, 36] and also a positive correlation between TSH and age only in women [33].

In our euthyroid sample, it was found a statistically significant negative correlation between TSH (but not thyroid hormones) and CD4 cell count. Also in multivariate analysis, after adjustment for age, gender and BMI, TSH levels remained negatively associated with CD4 cell count. This relationship with immune system was also described by other authors in HIV-infected population. Madeddu observed a negative correlation between TSH and CD4 cells nadir in HIV-infected patients on cART [26]. On the other hand, Collazos found a positive correlation between FT4 and CD4 cell count [37] and Beltran showed that low CD4 cell count was a risk factor for hypothyroidism [6]. This relationship is likely to be mediated by proinflammatory cytokines as tumor necrosis factor alpha (TNF- α), which has been found increased in HIV patients both before and during therapy and has receptors in thyroid follicular cells [26, 38]. In our study, FT3 and FT4 levels had a statistically significant positive correlation with the duration of HIV infection. However, in univariate and multivariate analysis, there was a lack of association between these parameters. There were no associations of thyroid function

regarding to the cART duration, which is not concordant with the positive correlation between TSH value and therapy duration described by Madeddu [26].

The influence of thyroid function on blood pressure homeostasis has been evaluated during the last years. Both overt and subclinical hypothyroidism are often associated with arterial hypertension (from 10 to 25% has diastolic hypertension), due to an increased systemic vascular resistance, increased arterial stiffness and changes in sodium homeostasis [39-41]. On the other hand, hyperthyroidism is a secondary cause of isolated systolic hypertension because FT3 reduces peripheral vascular resistance, increases heart rate and consequently raises cardiac output, leading to a widened pulse pressure [39, 40]. Even in euthyroid patients, thyroid function has been associated with blood pressure homeostasis [41-45], but unlike this sample previous studies only included HIV non-infected patients.

In our sample, TSH, FT3 and FT4 levels didn't differ significantly according to the presence of hypertension (only 38.2% had hypertension), but FT3 levels tended to be lower among hypertensive patients [$p = 0.051$ (data not shown)]. Some authors showed that euthyroid hypertensive patients had higher TSH levels [41-43]. Gumieniak reported that lower FT4 index (an estimative for FT4 values, resulting from the product of T4 total by the thyroid hormone binding ratio) and higher TSH levels within the normal range were linked to hypertension, independently of age, gender, BMI, race, smoking status and insulin sensibility. In his study, the lower FT4 index was an independent predictor of blood pressure salt-sensitivity, one of the key elements in the pathogenesis of hypertension [41].

In our study, it was only able to establish statistically significant correlations between thyroid hormones (but not TSH) and blood pressure. Serum FT3 was negatively correlated with both SBP and DBP and serum FT4 was negatively correlated only with DBP. It has been showed that FT3 and FT4 are direct vasodilator agents that promote relaxation of vascular smooth-muscle cells and of skeletal muscle resistance arterioles, with consequent decrease of systemic vascular resistance [40, 46], which justifies these results. However, in multiple linear regression model (with age, gender and BMI as covariates) there were no associations between FT3, FT4 and blood pressure. It was an expected result because age and BMI are positively associated with blood pressure [43].

Some studies have showed a positive association between TSH within the reference range and SBP and DBP, considering both hypertensive and normotensive subjects [42-44]. Iqbal observed a linear rise in DBP and also in SBP (but only in females) with the increase of normal range TSH quartile,

independently of age, BMI and smoking status [43]. In a cross-sectional study, Saltiki reported a positive correlation between TSH and DPB (not SBP), but not in multivariate analysis [44]. On the other hand, controversial studies didn't show relationship between blood pressure and thyroid function at the normal range [47, 48]. Gumieniak observed an excessive aggregation of high-normal TSH values in hypertensive families and a higher serum TSH levels in healthy subjects with family history of hypertension compared with those with negative family history. He suggested the existence of genetic variants affecting both blood pressure regulation and TSH levels [45].

Looking for BMI, patients with isolated central fat accumulation and with mixed forms of lipodystrophy had a significant higher mean of BMI. As expected, leptin mean levels were higher in patients with central fat accumulation and mixed forms, since leptin concentration is proportional to adipocyte mass [49]. In our sample, thyroid function into normal range didn't differ according to BMI and there was no significant correlation between these two parameters. It was only observed a negative association between BMI and FT4 in univariate (but not multivariate) analysis. In euthyroid HIV non-infected patients, previous studies found an association between BMI and changes in thyroid function, but this relationship could differ between lower grades of overweight and morbid obesity. Asvold e Nyrnes reported a positive association between BMI and TSH among men and women [13, 14], while Makepeace showed a significant inverse relationship between FT4 concentration and BMI in euthyroid subjects [15]. Michalaki showed that euthyroid morbidity obese subjects have raised T3, FT3, T4 and TSH levels compared with those not overweight [16]. This relationship seems to be changed by smoking status, but it is still controversial [13-15]. Indeed, some studies didn't found any association between thyroid function and BMI [34, 50]. The relationship between obesity and lipodystrophy in HIV-infected patients was already studied previously [19].

In our population, FT4 levels were negatively correlated with total cholesterol and LDL-C. In univariate analysis there was also found a positive association between FT4 levels and total cholesterol and LDL-C. However in the multiple linear regression model (with age, gender and BMI as covariates) only the association between FT4 and LDL-C remained statistically significant. There was no association between thyroid function and HDL-C and TG. Overt and subclinical hypothyroidism is associated with dyslipidemia [39]. According to previous studies including HIV non-infected patients, TSH within the reference range were positively associated with total cholesterol and LDL-C and

negatively with HDL-C [51]. Indeed, a large population-based study including 30000 subjects found that TSH levels were positively correlated with total cholesterol, LDL-C and TG and negatively correlated with HDL-C [52]. This association could be modified by the age, insulin sensitivity, smoking status and time since the last meal [51, 52].

As mentioned previously, this was the first study performed on HIV-infected patients to investigate the association between lipodystrophy and thyroid function at the normal range. One of the strengths of our study was the absence of inter-observer variability because all measurements were taken by the same practitioner. Also there was a careful adjustment for the main confounding factors as age, gender and BMI. However the present study has some limitations. There is a possible selection bias since all patients included were referred by the Infectious Disease specialist specifically for lipodystrophy or metabolic disorders related to cART. It cannot be discarded the influence of pre-HIV body composition, the cumulative exposure of each drug and the nadir value of CD4 cells, factors that could contribute to the risk of lipodystrophy or abdominal prominence that weren't evaluated. Due to a cross-sectional study, it was only able to establish associations and correlations, but not determine causality or risk factors between thyroid function and other variables. Finally, the studied sample was relatively small, there was homogeneity of age strata compared to other studies (only 15.5% of our sample were 60 years or older) and a lack of comparison with a seronegative control group. Therefore, further prospective larger studies are needed, starting before cART and with a controlled follow-up, to find additional associations and to determine causality between thyroid function and metabolic disorders related to cART.

CONCLUSION

TSH levels were positively associated with age and negatively with CD4 cell count, even in multivariate analysis. Despite of exclusion of patients with thyroid abnormalities from analysis, these results raised the interesting possibility that even in the normal range of thyroid function patients can have lipid abnormalities and raised blood pressure. So, thyroid function must be considered as a continuum spectrum from the euthyroid status to subclinical and overt thyroid dysfunction.

Our data suggest that thyroid function doesn't seem to be involved in body fat redistribution among HIV-infected patients at least at global serum level, but we do not discard that changes in local thyroid hormones availability occur in lipoatrophic or lipohypertrophic areas. However further studies are required at this issue.

LIST OF ABBREVIATIONS

AIDS - acquired immune deficiency syndrome;

BMI - body mass index;

cART - combined antiretroviral therapy;

CDC - Centers for Disease Control and Prevention;

CL - clinical lipodystrophy;

DIO2 - type 2 iodothyronine deiodinase;

DXA - dual-energy X-ray absorptiometry;

FMR - fat mass ratio;

FT3 - free 3,5,3'-triiodothyronine;

FT4 - free thyroxine;

HIV - human immunodeficiency virus;

IDF - International Diabetes Federation;

IQR - interquartile range;

LDL-C - low density lipoprotein cholesterol;

HDL-C - high-density lipoprotein cholesterol;

MCT8 - monocarboxylate transporter 8;

MS - metabolic syndrome;

NRTI - nucleoside reverse transcriptase inhibitors;

NNRTI - non-nucleoside reverse transcriptase inhibitors;

PI - protease inhibitors;

REE - resting energy expenditure;

SAT - subcutaneous adipose tissue;

SD - standard deviation;

TG - triglycerides;

TNF- α - tumor necrosis factor alpha;

TRs - thyroid hormone receptors;

TSH - thyrotropin.

COMPETING INTERESTS

The author declares that she has no competing interests.

ACKNOWLEDGMENTS

The author would like to sincerely thank M.D. Paula Freitas, for her excellent guidance throughout this project, with all her invaluable ideas and suggestions. Her dedication and encouragement were a strong motivation.

The author also expresses her gratitude to Professor Ana Cristina Santos for her continuous support in the statistical analysis, which made this project possible, and for her critical review of this manuscript.

The most sincere thank to Professor Davide Carvalho for the opportunity to develop this study in Department of Endocrinology, Diabetes and Metabolism of Centro Hospitalar São João.

Finally, the author is grateful to Professor António Sarmiento for the possibility to study patients who were referred from Infectious Diseases Outpatient Clinic, and to M.D. Jorge Pereira for proceeding DXA in Department of Nuclear Medicine.

REFERENCES

1. **HIV surveillance--United States, 1981-2008.** In: *MMWR Morb Mortal Wkly Rep.* vol. 60, 2011/06/04 edn; 2011: 689-693.
2. **Global report: UNAIDS World AIDS Day Report 2011.** In. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2011.
3. Grinspoon S, Carr A: **Cardiovascular risk and body-fat abnormalities in HIV-infected adults.** *The New England Journal of Medicine* 2005, **352**(1):48-62.
4. Önen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, Tebas P: **Aging and HIV infection: a comparison between older HIV-infected persons and the general population.** *HIV Clinical Trials* 2010, **11**(2):100-109.
5. Anuurad E, Semrad A, Berglund L: **Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.** *Metabolic Syndrome and Related Disorders* 2009, **7**(5):401-410.
6. Beltran S, Lescure FX, Desailoud R, Douadi Y, Smail A, El Esper I, Arlot S, Schmit JL, Thyroid and VIH Group: **Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening.** *Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America* 2003, **37**(4):579-583.
7. Garg A: **Acquired and inherited lipodystrophies.** *The New England Journal of Medicine* 2004, **350**(12):1220-1234.
8. Chen D, Misra A, Garg A: **Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.** *The Journal of Clinical Endocrinology and Metabolism* 2002, **87**(11):4845-4856.
9. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG: **An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.** *Lancet* 2003, **361**(9359):726-735.
10. Obregon MJ: **Thyroid hormone and adipocyte differentiation.** *Thyroid : official journal of the American Thyroid Association* 2008, **18**(2):185-195.

11. Viguerie N, Millet L, Avizou S, Vidal H, Larrouy D, Langin D: **Regulation of human adipocyte gene expression by thyroid hormone.** *The Journal of Clinical Endocrinology and Metabolism* 2002, **87**(2):630-634.
12. Rodriguez-Perez A, Palos-Paz F, Kaptein E, Visser TJ, Dominguez-Gerpe L, Alvarez-Escudero J, Lado-Abeal J: **Identification of molecular mechanisms related to nonthyroidal illness syndrome in skeletal muscle and adipose tissue from patients with septic shock.** *Clinical Endocrinology* 2008, **68**(5):821-827.
13. Asvold BO, Bjoro T, Vatten LJ: **Association of serum TSH with high body mass differs between smokers and never-smokers.** *The Journal of Clinical Endocrinology and Metabolism* 2009, **94**(12):5023-5027.
14. Nyrnes A, Jorde R, Sundsfjord J: **Serum TSH is positively associated with BMI.** *International Journal of Obesity (2005)* 2006, **30**(1):100-105.
15. Makepeace AE, Bremner AP, O'Leary P, Leedman PJ, Feddema P, Michelangeli V, Walsh JP: **Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and nonsmokers.** *Clinical Endocrinology* 2008, **69**(4):648-652.
16. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE: **Thyroid function in humans with morbid obesity.** *Thyroid : official journal of the American Thyroid Association* 2006, **16**(1):73-78.
17. **1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.** In: *MMWR Recomm Rep.* vol. 41, 1992/12/18 edn; 1992: 1-19.
18. Santos AC, Barros H: **Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community.** *Diabetes and Vascular Disease Research : official journal of the International Society of Diabetes and Vascular Disease* 2007, **4**(4):320-327.
19. Freitas P, Carvalho D, Santos AC, Matos MJ, Madureira AJ, Marques R, Martinez E, Sarmiento A, Medina JL: **Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy.** *Journal of Endocrinological Investigation* 2011.

20. **Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee.** In: *World Health Organization technical report series*. vol. 854, 1995/01/01 edn; 1995: 1-452.
21. Freitas P, Carvalho D, Souto S, Santos AC, Xerinda S, Marques R, Martinez E, Sarmento A, Medina JL: **Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients.** *BMC Infectious Diseases* 2011, **11**:246.
22. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr.: **Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.** *Circulation* 2009, **120**(16):1640-1645.
23. Freitas P, Santos AC, Carvalho D, Pereira J, Marques R, Martinez E, Sarmento A, Medina JL: **Fat mass ratio: an objective tool to define lipodystrophy in hiv-infected patients under antiretroviral therapy.** *Journal of Clinical Densitometry : the official journal of the International Society for Clinical Densitometry* 2010, **13**(2):197-203.
24. Bonnet E, Delpierre C, Sommet A, Marion-Latard F, Herve R, Aquilina C, Labau E, Obadia M, Marchou B, Massip P *et al*: **Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy.** *Journal of Clinical Densitometry : the official journal of the International Society for Clinical Densitometry* 2005, **8**(3):287-292.
25. Hoffmann CJ, Brown TT: **Thyroid function abnormalities in HIV-infected patients.** *Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America* 2007, **45**(4):488-494.
26. Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Solinas P, Mannazzu M, Falchi A, Mura MS, Madeddu G: **Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.** *Clinical Endocrinology* 2006, **64**(4):375-383.

27. Renard E, Fabre J, Paris F, Reynes J, Bringer J: **Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines.** *Clinical Endocrinology* 1999, **51**(2):223-230.
28. Lado-Abeal J, Calvo RM, Victoria B, Castro I, Obregon MJ, Araujo-Vilar D: **Regional decrease of subcutaneous adipose tissue in patients with type 2 familial partial lipodystrophy is associated with changes in thyroid hormone metabolism.** *Thyroid : official journal of the American Thyroid Association* 2010, **20**(4):419-424.
29. Hommes MJ, Romijn JA, Endert E, Sauerwein HP: **Increased resting energy expenditure in human immunodeficiency virus-infected men.** *The American Journal of Clinical Nutrition* 1991, **54**:311-315.
30. Pernerstorfer-Schoen H, Schindler K, Parschalk B, Schindl A, Thoeny-Lampert S, Wunderer K, Elmadfa I, Tschachler E, Jilma B: **Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.** *AIDS (London, England)* 1999, **13**(17):2389-2396.
31. Sutinen J, Yki-Järvinen H: **Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.** *American Journal of Physiology Endocrinology and Metabolism* 2007, **292**(3):E687-692.
32. al-Adsani H, Hoffer LJ, Silva JE: **Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement.** *The Journal of Clinical Endocrinology and Metabolism* 1997, **82**(4):1118-1125.
33. Roelfsema F, Pereira AM, Veldhuis JD, Adriaanse R, Endert E, Fliers E, Romijn JA: **Thyrotropin secretion profiles are not different in men and women.** *The Journal of Clinical Endocrinology and Metabolism* 2009, **94**(10):3964-3967.
34. Fernandez-Real JM, Lopez-Bermejo A, Castro A, Casamitjana R, Ricart W: **Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects.** *The Journal of Clinical Endocrinology and Metabolism* 2006, **91**(9):3337-3343.
35. Kratzsch J, Fiedler GM, Leichtle A, Brugel M, Buchbinder S, Otto L, Sabri O, Matthes G, Thierry J: **New reference intervals for thyrotropin and thyroid hormones based on National**

- Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid.** *Clinical Chemistry* 2005, **51**(8):1480-1486.
36. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE: **Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).** *The Journal of Clinical Endocrinology and Metabolism* 2002, **87**(2):489-499.
 37. Collazos J, Ibarra S, Mayo J: **Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era: evidence of an interrelation between the thyroid axis and the immune system.** *AIDS (London, England)* 2003, **17**(5):763-765.
 38. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML: **Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome.** *Blood* 2000, **95**(10):3191-3198.
 39. Biondi B, Klein I: **Hypothyroidism as a risk factor for cardiovascular disease.** *Endocrine* 2004, **24**(1):1-13.
 40. Klein I, Ojamaa K: **Thyroid hormone and the cardiovascular system.** *The New England Journal of Medicine* 2001, **344**(7):501-509.
 41. Gumieniak O, Perlstein TS, Hopkins PN, Brown NJ, Murphey LJ, Jeunemaitre X, Hollenberg NK, Williams GH: **Thyroid function and blood pressure homeostasis in euthyroid subjects.** *The Journal of Clinical Endocrinology and Metabolism* 2004, **89**(7):3455-3461.
 42. Asvold BO, Bjoro T, Nilsen TI, Vatten LJ: **Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based study.** *The Journal of Clinical Endocrinology and Metabolism* 2007, **92**(3):841-845.
 43. Iqbal A, Figenschau Y, Jorde R: **Blood pressure in relation to serum thyrotropin: The Tromso study.** *Journal of Human Hypertension* 2006, **20**(12):932-936.
 44. Saltiki K, Voidonikola P, Stamatelopoulos K, Mantzou E, Papamichael C, Alevizaki M: **Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: A cross-sectional study.** *Thyroid Research* 2008, **1**(1):3.

45. Gumieniak O HS, Perlstein TS, Ngumezi UC, Hopkins PN, Jeunemaitre X, Williams GH.: **Aggregation of high-normal thyroid-stimulating hormone in hypertensive families.** *The Journal of Clinical Endocrinology and Metabolism* 2005, **90**(11):5985-5990.
46. Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW: **The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries.** *Anesthesia and Analgesia* 1997, **85**(4):734-738.
47. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V: **Subclinical thyroid dysfunction and blood pressure: a community-based study.** *Clinical Endocrinology* 2006, **65**(4):486-491.
48. Van der Deure WM, Peeters RP, Uitterlinden AG, Hofman A, Breteler MM, Witteman J, Visser TJ: **Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study.** *Clinical Endocrinology* 2009, **71**(1):137-144.
49. Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, Gorden P: **Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.** *The Journal of Clinical Endocrinology and Metabolism* 2002, **87**(7):3110-3117.
50. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA: **Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects.** *Clinical Endocrinology* 2006, **64**(2):125-128.
51. Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO: **The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects.** *The Journal of Clinical Endocrinology and Metabolism* 2001, **86**(3):1206-1211.
52. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T: **The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study.** *European Journal of Endocrinology* 2007, **156**(2):181-186.

Table 1: Demographic and clinical characteristics according to four groups of body fat distribution.

	No lipodystrophy	Isolated central fat accumulation	Isolated lipoatrophy	Mixed forms of lipodystrophy	P
N (%)	42 (13.8)	85 (27.9)	95 (31.1)	83 (27.2)	
Demographics					
Gender [n (%)]					
Male	35 (83.3)	40 (47.1)	84 (88.4)	48 (57.8)	
Female	7 (16.7)	45 (52.9)	11 (11.6)	35 (42.2)	<0.001
Age [years, median (IQR)]	40.0 (16.0)	42.0 (18.5)	42.0 (10.0)	51.0 (17.0)	<0.001
Smoking history [n (%)]					
Never	13 (31.7)	44 (51.8)	21 (22.8)	41 (50.0)	
Current	24 (58.5)	25 (29.4)	58 (63.0)	21 (25.6)	
Former	4 (9.8)	16 (18.8)	13 (14.1)	20 (24.4)	<0.001
Anthropometrics					
Weight [kg, mean (SD)]	64.8 (8.3)	79.0 (14.3)	61.5 (9.6)	71.1 (13.1)	<0.001
Height [m, mean (SD)]	1.67 (0.10)	1.64 (0.09)	1.67 (0.08)	1.64 (0.10)	0.005
BMI [kg/m ² , mean (SD)]	23.0 (2.3)	29.5 (4.6)	21.9 (2.8)	26.5 (3.5)	<0.001
Hip circumference [cm, mean (SD)]	93.8 (4.3)	104.3 (8.5)	88.6 (5.1)	94.5 (6.0)	<0.001
Waist circumference [cm, mean (SD)]	84.1 (6.7)	102.1 (10.9)	83.0 (8.9)	92.4 (12.1)	<0.001
Thigh circumference [cm, mean (SD)]	46.8 (4.1)	52.0 (5.3)	44.8 (3.7)	47.4 (7.8)	<0.001
Neck circumference [cm, mean (SD)]	36.4 (3.4)	37.6 (3.8)	36.1 (3.2)	38.2 (4.2)	0.004
Arm circumference [cm, mean (SD)]	26.0 (2.9)	29.0 (2.8)	25.5. (2.6)	28.0 (4.8)	<0.001
Waist/hip ratio [mean (SD)]	0.90 (0.08)	0.98 (0.08)	0.94 (0.06)	1.03 (0.07)	<0.001
FMR by DXA [median (IQR)]	0.95 (0.78)	1.17 (0.52)	1.76 (1.36)	1.91 (1.39)	<0.001
Infectious					
HIV-infection [years, median (IQR)]	7.0 (5.0)	6.0 (6.0)	9.0 (5.0)	9.0 (5.0)	<0.001
HIV RNA (<50) [n (%)]					
Yes	32 (80.0)	69 (84.1)	86 (90.5)	75 (90.4)	
No	8 (20.0)	13 (15.9)	9 (9.5)	8 (9.6))	0.235
CD4 cell count (cells/mm ³)					

< 200 [n(%)]	5 (11.9)	4 (4.7)	8 (8.4)	7 (8.4)	
≥200 [n(%)]	37 (88.1)	81 (95.3)	87 (91.6)	76 (91.6)	0.505
CDC stage [n (%)]					
A	20 (47.6)	50 (58.8)	52 (55.3)	46 (55.4)	
B	3 (7.1)	1 (1.2)	0 (0.0)	0 (0.0)	
C	19 (45.2)	34 (40.0)	42 (44.7)	37 (44.6)	0.129
cART [years, median (IQR)]	4.0 (6.0)	4.0 (5.0)	8.0 (5.0)	8.0 (5.0)	<0.001
IP [n (%)]	25 (62.5)	51 (62.2)	52 (55.3)	38 (45.8)	0.029
NNRTI [n (%)]	18 (45.0)	35 (42.7)	47 (50.0)	45 (54.2)	0.169
NRTI [n (%)]	37 (92.5)	78 (95.1)	93 (98.9)	82 (98.8)	0.118
HIV risk factor [n (%)]					
Intravenous drug use	15 (35.7)	14 (16.7)	43 (45.7)	10 (12.0)	
Homosexual contact	5 (11.9)	4 (4.8)	12 (12.8)	11 (13.3)	
Heterosexual contact	22 (52.4)	66 (78.6)	33 (35.1)	59 (71.1)	
Other	0 (0.0)	0 (0.0)	6 (6.4)	3 (3.6)	<0.001
Cardiovascular Risk Factors					
SBP [mmHg, median (IQR)]	120.0 (20.0)	120.0 (30.0)	110.0 (20.0)	120.0 (20.0)	0.003
DBP [mmHg, median (IQR)]	80.0 (10.0)	80.0 (10.0)	80.0 (10.0)	80.0 (10.0)	0.733
Glucose [mg/dL, median (IQR)]	90.0 (23.0)	92.0 (23.0)	93.0 (27.0)	99.0 (39.0)	0.023
Total cholesterol [mg/dL, median (IQR)]	216.0 (60.0)	235.7 (58.9)	212.6 (56.8)	229.7 (73.0)	0.030
HDL-C [mg/dL, median (IQR)]	44.9 (12.0)	48.0 (13.8)	43.2 (13.1)	46.5 (11.9)	0.085
LDL-C [mg/dL, median (IQR)]	130.0 (48.6)	139.7 (48.0)	120.4 (45.3)	137.6 (51.1)	0.032
TG [mg/dL, median (IQR)]	213.0 (173.0)	178.0 (266.0)	231.0 (250.0)	242.0 (178.0)	0.234
Leptin [ng/mL, mean (SD)]	3.00 (3.72)	10.25 (9.91)	2.00 (1.78)	4.35 (4.97)	<0.001
Adiponectin [ng/mL, mean (SD)]	4735.5 (5865.6)	1898.0 (2595.0)	2990.0 (7539.2)	4338.4 (3829.5)	0.025

Table 2: Thyroid function according to the presence of lipodystrophy (clinically and FMR defined).

Lipodystrophy			
Clinical			
	Yes	No	p
TSH [mUI/mL, median (IQR)]	1.59 (1.08)	1.44 (1.18)	0.113
FT3 [pg/mL, median (IQR)]	2.98 (0.71)	2.97 (0.73)	0.792
FT4 [ng/dL, median (IQR)]	0.94 (0.20)	0.96 (0.20)	0.671
FMR			
	Yes	No	p
TSH [mUI/mL, median (IQR)]	1.53 (1.13)	1.55 (1.18)	0.437
FT3 [pg/mL, median (IQR)]	2.98 (0.73)	2.88 (0.76)	0.491
FT4 [ng/dL, median (IQR)]	0.92 (0.21)	0.92 (0.19)	0.864

Table 3: Thyroid function according to the four groups of body fat distribution.

	Lipodystrophy classified by the four groups of body fat distribution				p
	No lipodystrophy	Isolated central fat accumulation	Isolated lipoatrophy	Mixed forms of lipodystrophy	
TSH [mUI/mL, median (IQR)]	1.40 (1.09)	1.52 (1.50)	1.51 (0.94)	1.71 (1.21)	0.294
FT3 [pg/mL, median (IQR)]	2.97 (0.76)	2.98 (0.75)	3.07 (0.73)	2.84 (0.67)	0.126
FT4 [ng/dL, median (IQR)]	0.96 (0.16)	0.94 (0.84)	0.97 (0.24)	0.91 (0.18)	0.223

Table 4: Median levels of each parameter of thyroid function according to the presence of metabolic syndrome and its individual features.

	TSH [mUI/mL, median (IQR)]	FT3 [pg/mL, median (IQR)]	FT4 [ng/dL, median (IQR)]
High blood pressure (mmHg)			
Absent	1.53 (1.21)	3.05 (0.68)	0.95 (0.20)
Present	1.53 (1.10)	2.85 (0.69)	0.92 (0.19)
P	0.885	0.030	0.389
High fasting glucose (mg/dL)			
Absent	1.65 (1.36)	2.97 (0.61)	0.96 (0.24)
Present	1.51 (1.08)	3.01 (0.81)	0.94 (0.19)
P	0.108	0.429	0.154
Low HDL-C (mg/dL)			
Absent	1.52 (1.20)	3.00 (0.69)	0.95 (0.18)
Present	1.60 (1.15)	2.96 (0.75)	0.94 (0.21)
P	0.696	0.177	0.669
High TG (mg/dL)			
Absent	1.49 (1.22)	2.97 (0.69)	0.96 (0.19)
Present	1.57 (1.15)	3.00 (0.74)	0.94 (0.20)
P	0.613	0.788	0.680
Waist circumference (cm)			
Absent	1.54 (1.12)	3.04 (0.76)	0.96 (0.19)
Present	1.50 (1.20)	2.93 (0.71)	0.92 (0.20)
P	0.942	0.131	0.429
Metabolic syndrome			
Absent	1.52 (1.25)	3.00 (0.68)	0.96 (0.21)
Present	1.56 (1.09)	2.96 (0.80)	0.92 (0.20)
P	0.845	0.270	0.092

Table 5: Association between TSH levels and demographic and clinical characteristics.

	β	p	Adjusted β^*	p
TSH (mUI/mL)				
Age (years)	0.006	0.008	0.007	0.005
Gender	-0.020	0.726	0.0004	0.994
BMI (kg/m ²)	-0.005	0.391	-0.005	0.408
CD4 (cells/mm ³)	-0.108	0.005	-0.107	0.006

*-The coefficients were adjusted for age, gender and BMI.

Table 6: Association between FT3 levels and demographic and clinical characteristics.

	β	p	Adjusted β^*	p
FT3 (pg/mL)				
Age (years)	-0.022	0.424	-0.002	0.162
Gender	-0.002	0.001	-0.016	0.572
BMI (kg/m ²)	-0.003	0.269	-0.002	0.395
SBP (mmHg)	-0.001	0.074	-0.001	0.325
DBP (mmHg)	-0.001	0.103	-0.001	0.200
Duration of infection (years)	0.024	0.229	0.020	0.330

*-The coefficients were adjusted for age, gender and BMI.

Table 7: Association between FT4 levels and demographic and clinical characteristics.

	β	P	Adjusted β^*	p
FT4 (ng/dL)				
Age (years)	-0.001	0.575	-0.001	0.745
Gender	-0.062	0.096	-0.059	0.122
BMI (kg/m ²)	-0.008	0.035	-0.007	0.057
DBP (mmHg)	-0.002	0.158	-0.002	0.258
Total cholesterol (mg/dL)	-0.001	0.018	-0.001	0.064
LDL-C (mg/dL)	-0.001	0.002	-0.001	0.006
Duration of infection (years)	0.052	0.059	0.047	0.093

*-The coefficients were adjusted for age, gender and BMI.

Anexo I – Normas editoriais da Revista “BMC Infectious Diseases”

BMC Infectious Diseases

Instructions for authors – Research article

Assistance with the process of manuscript preparation and submission is available from [BioMed Central customer support team](#). See '[About this journal](#)' for information about policies and the refereeing process. We also provide a collection of links to [useful tools](#) and resources for scientific authors on our page.

Criteria

Research articles should report on original primary research, but may report on systematic reviews of published research provided they adhere to the appropriate reporting guidelines which are detailed in '[About this journal](#)'.

Submission process

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission and peer review.

Please note that *BMC Infectious Diseases* levies an article-processing charge on all accepted Research article, Case report, Database, Debate, Software, Study protocol and Technical advance articles; if the submitting author's institution is a [BioMed Central member](#) the cost of the article-processing charge may be covered by the membership (see [About](#) page for detail). Please note that the membership is only automatically recognised on submission if the submitting author is based at the member institution.

To facilitate rapid publication and to minimize administrative costs, *BMC Infectious Diseases* accepts only [online submission](#).

Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time; when users return to the site, they can carry on where they left off.

See below for examples of [word processor](#) and [graphics file formats](#) that can be accepted for the main manuscript document by the online submission system. Additional files of any type, such as [movies](#), animations, or [original data files](#), can also be submitted as part of the manuscript.

During submission you will be asked to provide a cover letter. Use this to explain why your manuscript should be published in the journal, to elaborate on any issues relating to our editorial policies in the '[About BMC Infectious Diseases](#)' page, and to declare any potential competing interests. You will be also asked to provide the contact details (including email addresses) of potential peer reviewers for your manuscript. These should be experts in their field, who will be able to provide an objective assessment of the manuscript. Any suggested peer reviewers should not have published with any of the authors of the manuscript within the past five years, should not be current collaborators, and should not be members of the same research institution. Suggested reviewers will be considered alongside potential reviewers recommended by the Editorial team, Editorial Advisors, Section Editors and Associate Editors.

Assistance with the process of manuscript preparation and submission is available from [BioMed Central customer support team](#).

We also provide a collection of links to useful tools and resources for scientific authors on our [Useful Tools](#) page.

File formats

The following word processor file formats are acceptable for the main manuscript document:

- Microsoft Word (version 2 and above)
- Rich text format (RTF)
- Portable document format (PDF)
- TeX/LaTeX (use [BioMed Central's TeX template](#))
- DeVice Independent format (DVI)

Users of other word processing packages should save or convert their files to RTF before uploading. Many free tools are available which ease this process.

TeX/LaTeX users: We recommend using [BioMed Central's TeX template and BibTeX stylefile](#). If you use this standard format, you can submit your manuscript in TeX format. If you have used another template for your manuscript, or if you do not wish to use BibTeX, then please submit your manuscript as a DVI file. We do not recommend converting to RTF.

Note that figures must be submitted as separate image files, not as part of the submitted manuscript file.

Preparing main manuscript text

General guidelines of the journal's style and language are given [below](#).

Overview of manuscript sections for Research article

Manuscripts for Research article articles submitted to *BMC Infectious Diseases* should be divided into the following sections (in this order):

- [Title page](#)
- [Abstract](#)
- [Keywords](#)
- [Background](#)
- [Methods](#)
- [Results and discussion](#)
- [Conclusions](#)
- [List of abbreviations used](#) (if any)
- [Competing interests](#)
- [Authors' contributions](#)
- [Authors' information](#)
- [Acknowledgements](#)
- [Endnotes](#)
- [References](#)
- [Illustrations and figures](#) (if any)
- [Tables and captions](#)
- [Preparing additional files](#)

The **Accession Numbers** of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name; for example,

[EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].

The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database ([EMBL](#)), DNA Data Bank of Japan ([DDBJ](#)), GenBank at the NCBI ([GenBank](#)), Protein Data Bank ([PDB](#)), Protein Information Resource ([PIR](#)) and the Swiss-Prot Protein Database ([Swiss-Prot](#)).

You can [download a template](#) (Mac and Windows compatible; Microsoft Word 98/2000) for your article.

For reporting standards please see the information in the [About](#) section.

Title page

The title page should:

- provide the title of the article
- list the full names, institutional addresses and email addresses for all authors
- indicate the corresponding author

Please note:

- the title should include the study design, for example "A versus B in the treatment of C: a randomized controlled trial X is a risk factor for Y: a case control study"
- abbreviations within the title should be avoided

Abstract

The Abstract of the manuscript should not exceed 350 words and must be structured into separate sections: **Background**, the context and purpose of the study; **Methods**, how the study was performed and statistical tests used; **Results**, the main findings; **Conclusions**, brief summary and potential implications. Please minimize the use of abbreviations and do not cite references in the abstract. **Trial registration**, if your Research article reports the results of a controlled health care intervention, please list your trial registry, along with the unique identifying number (e.g. **Trial registration**: Current Controlled Trials ISRCTN73824458). Please note that there should be no space between the letters and numbers of your trial registration number. We recommend manuscripts that report randomized controlled trials follow the [CONSORT extension for abstracts](#).

Keywords

Three to ten keywords representing the main content of the article.

Background

The Background section should be written in a way that is accessible to researchers without specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the background to the research and its aims. Reports of clinical research should, where appropriate, include a summary of a search of the literature to indicate why this study was necessary and what it aimed to contribute to the field. The section should end with a brief statement of what is being reported in the article.

Methods

The methods section should include the design of the study, the setting, the type of participants or materials involved, a clear description of all interventions and comparisons, and the type of analysis used, including a power

calculation if appropriate. Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses in the Methods section.

For studies involving human participants a statement detailing ethical approval and consent should be included in the methods section. For further details of the journal's editorial policies and ethical guidelines see '[About this journal](#)'.

For further details of the journal's data-release policy, see the policy section in '[About this journal](#)'.

Results and discussion

The Results and discussion may be combined into a single section or presented separately. Results of statistical analysis should include, where appropriate, relative and absolute risks or risk reductions, and confidence intervals. The Results and discussion sections may also be broken into subsections with short, informative headings.

Conclusions

This should state clearly the main conclusions of the research and give a clear explanation of their importance and relevance. Summary illustrations may be included.

List of abbreviations

If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.

Competing interests

A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests; they should also reveal any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.

Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

When completing your declaration, please consider the following questions:

Financial competing interests

- In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
- Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
- Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
- Do you have any other financial competing interests? If so, please specify.

Non-financial competing interests

Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.

If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.

Authors' contributions

In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript should be specified in this section.

An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.

We suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

All contributors who do not meet the criteria for authorship should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support.

Authors' information

You may choose to use this section to include any relevant information about the author(s) that may aid the reader's interpretation of the article, and understand the standpoint of the author(s). This may include details about the authors' qualifications, current positions they hold at institutions or societies, or any other relevant background information. Please refer to authors using their initials. Note this section should not be used to describe any competing interests.

Acknowledgements

Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible.

The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.

Endnotes

Endnotes should be designated within the text using a superscript lowercase letter and all notes (along with their corresponding letter) should be included in the Endnotes section. Please format this section in a paragraph rather than a list.

References

All references, including URLs, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, followed by any in tables or legends. Each reference must have an individual reference number. Please avoid excessive referencing. If automatic numbering systems are used, the reference numbers must be finalized and the bibliography must be fully formatted before submission.

Only articles, datasets and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited; unpublished abstracts, unpublished data and personal communications should not be included in the reference list, but may be included in the text and referred to as "unpublished observations" or "personal communications" giving the names of the involved researchers. Obtaining permission to quote personal communications and unpublished data from the cited colleagues is the responsibility of the author.

Footnotes are not allowed, but endnotes are permitted. Journal abbreviations follow Index Medicus/MEDLINE. Citations in the reference list should include all named authors, up to the first 30 before adding '*et al.*'.

Any *in press* articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.

Style files are available for use with popular bibliographic management software:

- [BibTeX](#)
- [EndNote style file](#)
- [Reference Manager](#)
- [Zotero](#)

Examples of the *BMC Infectious Diseases* reference style are shown [below](#). Please ensure that the reference style is followed precisely; if the references are not in the correct style they may have to be retyped and carefully proofread.

All web links and URLs, including links to the authors' own websites, should be given a reference number and included in the reference list rather than within the text of the manuscript. They should be provided in full, including both the title of the site and the URL, in the following format: **The Mouse Tumor Biology Database** [<http://tumor.informatics.jax.org/mtbwi/index.do>]. If an author or group of authors can clearly be associated with a web link, such as for weblogs, then they should be included in the reference.

Examples of the BMC Infectious Diseases reference style

Article within a journal

Koonin EV, Altschul SF, Bork P: **BRCA1 protein products: functional motifs.** *Nat Genet* 1996,**13**:266-267.

Article within a journal supplement

Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: **Analysis and assessment of ab initio three-dimensional prediction, secondary structure, and contacts prediction.** *Proteins* 1999,**43**(Suppl 3):149-170.

In press article

Kharitonov SA, Barnes PJ: **Clinical aspects of exhaled nitric oxide.** *Eur Respir J*, in press.

Published abstract

Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: **Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis [abstract].** *Arthritis Rheum* 1999, **42**:s250.

Article within conference proceedings

Jones X: **Zeolites and synthetic mechanisms.** In *Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore*. Edited by Smith Y. Stoneham: Butterworth-Heinemann; 1996:16-27.

Book chapter, or article within a book

Schnepf E: **From prey via endosymbiont to plastids: comparative studies in dinoflagellates.** In *Origins of Plastids. Volume 2*. 2nd edition. Edited by Lewin RA. New York: Chapman and Hall; 1993:53-76.

Whole issue of journal

Ponder B, Johnston S, Chodosh L (Eds): **Innovative oncology.** In *Breast Cancer Res* 1998, **10**:1-72.

Whole conference proceedings

Smith Y (Ed): *Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore*. Stoneham: Butterworth-Heinemann; 1996.

Complete book

Margulis L: *Origin of Eukaryotic Cells*. New Haven: Yale University Press; 1970.

Monograph or book in a series

Hunninghake GW, Gadek JE: **The alveolar macrophage.** In *Cultured Human Cells and Tissues*. Edited by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): *Methods and Perspectives in Cell Biology*, vol 1.]

Book with institutional author

Advisory Committee on Genetic Modification: *Annual Report*. London; 1999.

PhD thesis

Kohavi R: **Wrappers for performance enhancement and oblivious decision graphs.** *PhD thesis*. Stanford University, Computer Science Department; 1995.

Link / URL

The Mouse Tumor Biology Database [<http://tumor.informatics.jax.org/mtbwi/index.do>]

Link / URL with author(s)

Neylon C: Open Research Computation: an ordinary journal with extraordinary aims. [http://blogs.openaccesscentral.com/blogs/bmcblog/entry/open_research_computation_an_ordinary]

Dataset with persistent identifier

Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, H-C (2011): Genome data from sweet and grain sorghum (*Sorghum bicolor*). *GigaScience*.<http://dx.doi.org/10.5524/100012>.

Preparing illustrations and figures

Illustrations should be provided as separate files, not embedded in the text file. Each figure should include a single illustration and should fit on a single page in portrait format. If a figure consists of separate parts, it is important that a single composite illustration file be submitted which contains all parts of the figure. There is no charge for the use of color figures.

Please read our [figure preparation guidelines](#) for detailed instructions on maximising the quality of your [figures](#).

Formats

The following file formats can be accepted:

- EPS (preferred format for diagrams)
- PDF (also especially suitable for diagrams)
- TIFF
- PNG (preferred format for photos or images)
- Microsoft Word (version 5 and above; figures must be a single page)
- PowerPoint (figures must be a single page)
- JPEG
- BMP

Figure legends

The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file. For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words.

Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have previously been published elsewhere.

Preparing a personal cover page

If you wish to do so, you may submit an image which, in the event of publication, will be used to create a cover page for the PDF version of your article. The cover page will also display the journal logo, article title and citation details. The image may either be a figure from your manuscript or another relevant image. You must have permission from the copyright to reproduce the image. Images that do not meet our requirements will not be used. Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image).

Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen dumps), JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw).

Preparing tables

Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends may then follow, but they should be concise. Tables should always be cited in text in consecutive numerical order.

Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 portrait or landscape format. These will be typeset and displayed in the final published form of the article. Such tables should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned when the file is sent electronically for review; this will not always be the case if columns are generated by simply using tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should not be used to indicate numerical values. Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in a table legend. Tables should not be embedded as figures or spreadsheet files.

Larger datasets or tables too wide for a portrait page can be uploaded separately as additional files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.

Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or comma separated values (.csv). As with all files, please use the standard file extensions.

Preparing additional files

Although *BMC Infectious Diseases* does not restrict the length and quantity of data included in an article, there may still be occasions where an author wishes to provide data sets, tables, movie files, or other information as additional files. Results that would otherwise be indicated as "data not shown" can and should be included as additional files. Since many weblinks and URLs rapidly become broken, *BMC Infectious Diseases* requires that all supplementary data are included as additional files rather than as a link to your own website. These files can be uploaded using the 'Additional Material files' button in the manuscript submission tool.

The maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission. Additional files will be linked to the final published article in the form supplied by the author, but will not be displayed within the article. They will be made available in exactly the same form as originally provided by the authors.

If additional material is provided, please list the following information in a separate section of the manuscript text, immediately following the tables (if any):

- File name (e.g. Additional file 1)
- File format including the three-letter file extension (including name and a URL of an appropriate viewer if format is unusual)
- Title of data
- Description of data

Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name within the body of the article, e.g. 'An additional movie file shows this in more detail [see Additional file 1]'.

Additional file formats

Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely available tools. The following are examples of suitable formats.

- Additional documentation
 - PDF (Adobe Acrobat)

- Animations
 - SWF (Shockwave Flash)
- Movies
 - MOV (QuickTime)
 - MPG (MPEG)
- Tabular data
 - XLS (Excel Spreadsheet)
 - CSV (Comma separated values)

As with figure files, files should be given the standard file extensions. This is especially important for Macintosh users, since the Mac OS does not enforce the use of standard extensions. Please also make sure that each additional file is a single table, figure or movie (please do not upload linked worksheets or PDF files larger than one sheet).

Mini-websites

Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from within the full text HTML version of the article. In order to do this, please follow these instructions:

1. Create a folder containing a starting file called index.html (or index.htm) in the root.
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders.
3. Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My Documents\mini-website\images\picture.jpg") and no link is longer than 255 characters.
4. Access the index.html file and browse around the mini-website, to ensure that the most commonly used browsers (Internet Explorer and Firefox) are able to view all parts of the mini-website without problems, it is ideal to check this on a different machine.
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the ZIP, and that the file has .zip extension, then submit as an additional file with your article.

Style and language

General

Currently, *BMC Infectious Diseases* can only accept manuscripts written in English. Spelling should be US English or British English, but not a mixture.

There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise. There is also no restriction on the number of figures, tables or additional files that can be included with each article online.

Figures and tables should be numbered in the order in which they are referred to in the text. Authors should include all relevant supporting data with each article.

BMC Infectious Diseases will not edit submitted manuscripts for style or language; reviewers may advise rejection of a manuscript if it is compromised by grammatical errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. In-house copyediting will be minimal. Non-native speakers of English may choose to make use of a copyediting service.

Language editing

For authors who wish to have the language in their manuscript edited by a native-English speaker with scientific expertise, BioMed Central recommends [Edanz](#). BioMed Central has arranged a 10% discount to the fee charged to BioMed Central authors by Edanz. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. Please contact [Edanz](#) directly to make arrangements for editing, and for pricing and payment details.

Help and advice on scientific writing

The abstract is one of the most important parts of a manuscript. For guidance, please visit our page on [Writing titles and abstracts for scientific articles](#).

Tim Albert has produced for BioMed Central a [list of tips](#) for writing a scientific manuscript. [American Scientist](#) also provides a list of resources for science writing.

Abbreviations

Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of abbreviations can be provided following the main manuscript text.

Typography

- Please use double line spacing.
- Type the text unjustified, without hyphenating words at line breaks.
- Use hard returns only to end headings and paragraphs, not to rearrange lines.
- Capitalize only the first word, and proper nouns, in the title.
- All pages should be numbered.
- Use the *BMC Infectious Diseases* [reference format](#).
- Footnotes are not allowed, but endnotes are permitted.
- Please do not format the text in multiple columns.
- Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full. **Please ensure that all special characters used are embedded in the text, otherwise they will be lost during conversion to PDF.**

Units

SI units should be used throughout (liter and molar are permitted, however).